Wardatul Jannah

Wardatul Jannah

Auto-generated profile, based on publicly available information

Wardatul Jannah

Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Indonesia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
WJWardatul Jannah
Wardatul Jannah
QKQisty Khoiry
Qisty Khoiry
SASofa Dewi Alfian
Sofa Dewi Alfian
RARizky Abdulah
Rizky Abdulah
Purpose: To identify the suitability of pharmacy-based measures for determining medication adherence in routine clinical use. Methods: Data were obtained through PubMed and Scopus databases up to December 2023 without publication year restrictions. This review included English studies on assessing medication adherence for hypertension, hyperlipidemia, asthma, chronic obstructive pulmonary disease, and diabetes, using pharmacy databases and providing full-text access. We investigated evidence quality utilizing the Newcastle–Ottawa Scale for non-randomized studies (cohort, case-control, and cross-sectional) and the Risk of Bias Assessment Tool for Non-randomized Studies-2 and JADAD scales for quasi-experiments and randomized control trials, respectively. We determined validity characteristics (completeness, accuracy, reliability, objectivity, continuous adherence history, non-intrusiveness, sensitivity, and specificity) and applicability (cost-effectiveness, ease of use, and interpretability) to evaluate the suitability of pharmacy-based medication adherence measures in clinical settings. Results: This review retrieved 1513 studies, of which 74 met the inclusion criteria. All of the studies, which were published from 2000 to 2023 and mostly utilized a retrospective cohort design (n = 53), included 17.6 million patients. Of the 74 studies, 50 were conducted in the United States. Diabetes mellitus (n = 40) was the most prevalent disease, whereas the medication possession ratio (n = 46) and prescription days covered (n = 31) were the most prevalent pharmacy-based matrix. According to the results, 73 articles demonstrated validity characteristics, whereas 1 article lacked these characteristics. All 74 (100%) articles had applicability characteristics. Conclusion: This systematic review demonstrates that pharmacy-based measures possess valid characteristics, including comprehensive, accurate, objective, reliable, and continuously updated adherence history records. These measures are designed to minimize disruption while offering high sensitivity and specificity. Furthermore, they are characterized by their practicality, being cost-effective, easy to implement, and easy to interpret. These findings suggest that pharmacy-based measures are potentially suitable to assess medication adherence for routine clinical use.

1 April 2025 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
WJWardatul Jannah
Wardatul Jannah
SASofa Dewi Alfian
Sofa Dewi Alfian
RARizky Abdulah
Rizky Abdulah
Purpose: To identify psychosocial and sociodemographic factors influencing low medication awareness among patients with Chronic obstructive pulmonary disease (COPD) based on Indonesian Family Life Survey 5 (IFLS-5). Methods: This study used a cross-sectional design, with data from IFLS-5 (2014/2015). Inclusion criteria were subjects with a self-reported diagnosis of COPD and aged at least 15 years. Two main factors were identified as modifiable psychosocial factors (eg, insomnia, depressive symptoms, happiness status, general health check status, smoking status, and health service satisfaction) and as non-modifiable sociodemographic factors (eg, gender, age, education level, marital status, economic status, insurance ownership, religiosity, comorbidity, and place of residence). Multivariate logistic regression analysis was used to explore the relationship between these factors and the awareness of COPD medication, by observing the adjusted odds ratio (aOR) within a 95% Confidence Interval. Results: There were 618 subjects identified with COPD, of which 53.40% were male. 84.30% of subjects have low medication awareness. Non-modifiable sociodemographic factors such as age 15– 25 years (aOR: 2.531; 95% CI 1.024– 6.253; p-value 0.044), age 26– 35 years (aOR: 3.418; 95% CI 1.444– 8.091; p-value 0.005), high school education level (aOR: 4.870; 95% CI 1.685– 14.078; p-value 0.003), and modifiable psychosocial factors such as satisfaction with health services with the category “sufficient” (aOR: 2.510; 95% CI 510; 95% CI 1.508– 4.176; p-value 0.000), and subjects who smoked (aOR: 1.894; 95% CI 1.147– 3.127; p-value 0.013), were significantly associated with low COPD medication awareness. Conclusion: This study shows that most subjects with COPD had low medication awareness, which is influenced by factors such as age, education level, smoking habits, and satisfaction with health services. This highlights the need for targeted interventions for high-risk groups. Limitations of this study include reliance on self-reported data, which may lead to recall bias. In addition, this study was unable to provide evidence of a causal relationship.

30 December 2024 in Journal of HIV/AIDS & Social Services
Verified
Journal Article
Closed access
DPDimas Setyadi Putra
Dimas Setyadi Putra
WJWardatul Jannah
Wardatul Jannah
BSBachren Azra Saputra
Bachren Azra Saputra

1 January 2026 in Journal of Nutrition and Metabolism
Verified
Journal Article
Open access
MAMarissa Arifin
Marissa Arifin
WJWardatul Jannah
Wardatul Jannah
NZNeily Zakiyah
Neily Zakiyah
AMAnna Meiliana
Anna Meiliana
MBMelisa Intan Barliana
Melisa Intan Barliana
KLKeri Lestari
Keri Lestari
Background: Fructose consumption has significantly increased in recent years and is associated with hepatic oxidative stress, playing a major role in metabolic diseases such as metabolic‐associated fatty liver disease (MAFLD). This systematic review aimed to summarize how excessive fructose consumption causes liver injury through oxidative stress, leading to lipid accumulation in hepatic cells. Methods: PubMed, Scopus, and Web of Science databases were systematically searched (2019–2024) for preclinical studies using fructose‐only diets. Criteria were applied to identify relevant studies. The primary outcome was hepatic oxidative stress, and the secondary outcomes included weight, metabolic markers, liver function, and histopathology changes. Two reviewers assessed bias risk using SYRCLE. Results: Among 517 studies screened, 26 met the inclusion criteria. Most studies had unclear bias risk due to poor reporting. Low‐dose fructose intake (10%) over 8–12 weeks induced hepatic oxidative stress, indicated by elevated malondialdehyde (MDA) in 53.8% of cases, increased reactive oxygen species (ROS) in 19.2%, and reduced antioxidant defenses, including glutathione (GSH), GSH peroxidase (GSH‐Px), and superoxide dismutase (SOD) in 38.5%. Four studies showed early upregulation of antioxidant responses (11.5%), suggesting initial adaptation. Prolonged fructose exposure (up to 36 weeks) caused sustained liver injury due to overwhelming defenses and increased oxidative stress. Most studies also reported metabolic disturbances, liver dysfunction, and lipid accumulation. Conclusion: This systematic review showed that excessive fructose consumption induces liver injury through oxidative stress, which then triggers subsequent processes like inflammation. Overconsumption led to uncontrolled hepatic metabolism, increasing lipid synthesis, metabolic overload, overproduction of ROS, impairment of antioxidant defenses, and histopathological changes.

18 August 2026 in BMJ Nutrition, Prevention & Health
Verified
Journal Article
Open access
PDF file
MAMarissa Arifin
Marissa Arifin
WJWardatul Jannah
Wardatul Jannah
ILIrma Rahayu Latarissa
Irma Rahayu Latarissa
NZNeily Zakiyah
Neily Zakiyah
AMAnna Meiliana
Anna Meiliana
KLKeri Lestari
Keri Lestari
Background: Excessive dietary fructose has been implicated in the pathogenesis of metabolic dysfunction-associated fatty liver disease (MAFLD), yet its specific role in driving hepatic inflammation remains incompletely defined. This systematic review aimed to synthesise recent preclinical evidence on the inflammatory and oxidative mechanisms linking fructose-only diets to hepatic injury and MAFLD progression. Methods: The databases PubMed, Scopus and Web of Science were systematically searched from 2019 to 2024. Eligible studies included preclinical studies that assessed hepatic inflammation and injury following fructose-only diets. Data on inflammatory biomarkers, oxidative stress, histopathology and metabolic parameters were extracted, and the study quality was evaluated using the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies checklist. Results: 14 eligible studies met the inclusion criteria and demonstrated consistent upregulation of pro-inflammatory cytokines (eg, tumour necrosis factor-α, interleukin (IL)-6, IL-1β), activation of nuclear factor kappa-light-chain-enhancer of activated B cells and NOD-like receptor family pyrin domain containing 3 inflammasome pathways and increased oxidative stress markers (eg, malondialdehyde, reactive oxygen species, uric acid). Histological evidence of steatosis, ballooning and inflammation was observed across models, independent of additional dietary stressors. IL-10 was elevated in one study but failed to counteract lipogenesis. Most studies showed moderate to high methodological quality, but the lack of sample size calculations and blinding indicates potential risk of bias and should be considered when interpreting the findings. Conclusion: This systematic review demonstrates that fructose acts as both a substrate for de novo lipogenesis and an upstream activator of inflammatory signalling, thereby creating a cycle between metabolism and immunity. This mechanistic link explains the progression from simple steatosis to steatohepatitis and fibrosis. Targeting inflammatory pathways while reducing dietary fructose offers a potential strategy for the prevention and therapy of MAFLD. PROSPERO registration number: CRD420251077702.

1 October 2026 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
SASofa Dewi Alfian
Sofa Dewi Alfian
WJWardatul Jannah
Wardatul Jannah
SCSusan F Candradewi
Susan F Candradewi
WIWidya Norma Insani
Widya Norma Insani
BVBernard Vrijens
Bernard Vrijens
RARizky Abdulah
Rizky Abdulah
Background: Despite the availability of various frameworks for studying medication adherence, most fail to account for the distinct characteristics of each phase of medication-taking behavior based on the ABC Taxonomy (initiation, implementation, and discontinuation). To address this gap, existing frameworks should be systematically mapped in alignment with the ABC taxonomy to reflect unique conceptual distinctions across these phases. Purpose: To assess and classify the theoretical frameworks used in medication adherence research based on the ABC taxonomy. Methods: A systematic literature search was conducted in PubMed and Scopus on 4 June 2025, without publication year restrictions. Eligible studies were empirical medication adherence studies that explicitly applied an identifiable theoretical or conceptual framework to understand, explain, or predict medication adherence and its determinants, or to design, guide, or evaluate interventions aimed at improving medication adherence. The identified frameworks were subsequently mapped to the three medication adherence phases defined by the ABC Taxonomy. The methodological quality of the included studies was critically appraised using the Mixed Methods Appraisal Tool (MMAT), version 2018. Results: Of 855 retrieved records, 29 met the inclusion criteria, representing 27 distinct theoretical frameworks. Most studies were conducted in the United States (n = 8; 27.58%) and among patients with multiple chronic conditions (n = 6; 20.68%). Only three frameworks (11.1%) addressed all three phases of medication adherence, whereas 20 frameworks (74.07%) focused solely on the implementation phase; three frameworks (11.11%) on implementation and discontinuation, and one examined initiation (3.7%). Most studies (n = 23; 79.31%) used frameworks to conceptualize and explain the multifaceted determinants of medication adherence. Conclusion: While numerous frameworks have been proposed to understand medication adherence, most predominantly emphasize the implementation phase, leaving the initiation and discontinuation phases underexplored. Current frameworks are predominantly employed to explain factors, predictors, and underlying mechanisms that influence adherence behaviors.